Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
NDC API
0
VMF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Jai Radhe Sales is your partner for all your sourcing needs.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
JDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]KDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Jai Radhe Sales is your partner for all your sourcing needs.
About the Company : Jai Radhe Sales was founded in 1999 as an out-of-the-box distribution firm specializing in the global supply of high-quality pharmaceutical ingredients. The firm provides complete ...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Annual Reports
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
APIs
Reply
24 May 2025
Reply
03 Mar 2023
Reply
06 Aug 2020
Reply
22 Jul 2020
Reply
24 Jan 2019
Reply
19 Jan 2019
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
REF. STANDARDS & IMPURITIES
Others
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
53
PharmaCompass offers a list of Voglibose API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Voglibose manufacturer or Voglibose supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Voglibose manufacturer or Voglibose supplier.
PharmaCompass also assists you with knowing the Voglibose API Price utilized in the formulation of products. Voglibose API Price is not always fixed or binding as the Voglibose Price is obtained through a variety of data sources. The Voglibose Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine, including repackagers and relabelers. The FDA regulates 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine supplier is an individual or a company that provides 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine active pharmaceutical ingredient (API) or 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine finished formulations upon request. The 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine suppliers may include 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine API manufacturers, exporters, distributors and traders.
click here to find a list of 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine Drug Master File in Japan (3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine JDMF) empowers 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine JDMF during the approval evaluation for pharmaceutical products. At the time of 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine Drug Master File in Korea (3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine. The MFDS reviews the 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine KDMF as part of the drug registration process and uses the information provided in the 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine KDMF to evaluate the safety and efficacy of the drug.
After submitting a 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine API can apply through the Korea Drug Master File (KDMF).
click here to find a list of 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine suppliers with KDMF on PharmaCompass.
3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine GMP manufacturer or 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine GMP API supplier for your needs.
A 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine CoA (Certificate of Analysis) is a formal document that attests to 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine's compliance with 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine specifications and serves as a tool for batch-level quality control.
3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine CoA mostly includes findings from lab analyses of a specific batch. For each 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine may be tested according to a variety of international standards, such as European Pharmacopoeia (3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine EP), 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol; N-(1,3-Dihydroxyprop-2-yl)valiolamine USP).
Comment (3)
